OKYO Pharma Urcosimod Abstract Accepted
Analysis based on 7 articles · First reported Jan 30, 2026 · Last updated Jan 30, 2026
The acceptance of OKYO Pharma's abstract for presentation at a prestigious medical meeting is a positive development, potentially increasing investor confidence in the company's lead candidate, urcosimod. This could lead to a positive impact on OKYO Pharma's stock price and overall market sentiment for the biotechnology sector focused on ophthalmic treatments.
OKYO Pharma, a clinical-stage biopharmaceutical company, announced that an abstract on its lead candidate, urcosimod (formerly OK-101), has been accepted for presentation at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting. The abstract, titled 'Evaluation of Urcosimod in Neuropathic Corneal Pain: Efficacy and Safety Results from a Proof-of-Concept Pilot Phase 2 Study', will be presented on April 11, 2026, in Washington, DC. This acceptance follows a competitive review process and highlights positive efficacy and safety data from OKYO Pharma's recently completed proof-of-concept Phase 2 study of urcosimod in patients with neuropathic corneal pain. Robert Dempsey, CEO of OKYO Pharma, emphasized the potential of urcosimod as a novel therapeutic. Urcosimod has also received IND approval and fast track designation from the United States===Food and Drug Administration. OKYO Pharma plans to initiate a larger 150-patient Phase 2b/3 multiple-dose study of urcosimod in the first half of 2026.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard